Breathing Adapted Radiotherapy for Mediastinal Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00928096|
Recruitment Status : Completed
First Posted : June 25, 2009
Last Update Posted : October 21, 2014
|Condition or disease|
Radiotherapy using a breathing adapted therapy scan is a routine technique in breast cancer. Breathing adapted radiotherapy may also reduce radiation dose to organs at risk, e.g. heart and lung, in patients with mediastinal Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.
Optimal radiation therapy of these lymphoma patients includes radiotherapy planning using pre-chemotherapy PET-scanning, fused with a post-chemo planning CT-scan. This makes accurate treatment of pre-chemo involved volume possible and also accurate radiation of the post-chemo involved volume possible. Thus, the optimal breathing adapted radiation requires planning using a breathing adapted pre-chemo PET-CT scan fused with a breathing adapted post-chemo planning CT scan. In this study, 20 consecutive patients with mediastinal Hodgkin lymphoma and aggressive non-Hodgkin lymphomas will have combination therapy with chemotherapy and radiation therapy to involved nodes. Two radiation therapy plans will be made for each patient: one using a breathing adapted pre-chemo PET-CT scan fused with a post-chemo planning CT scan, and one using the standard procedure of a pre-chemo PET-CT scan fused with post-chemo planning CT scan. Dose levels to the lymphoma and to the organs of risk will be compared in each patient. The best radiation therapy plan will be used to treat the patient.
|Study Type :||Observational|
|Actual Enrollment :||22 participants|
|Official Title:||Breathing Adapted Radiotherapy for Mediastinal Lymphoma|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||May 2013|
|Actual Study Completion Date :||May 2013|
- Estimated radiation dose levels to the lymphoma and to the organs of risk [ Time Frame: Before day 1 of radiation therapy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00928096
|Department of Hematology and Department of Radiation Oncology, Copenhagen University Hospital, Rigshospitalet|
|Copenhagen, Denmark, DK2100|
|Principal Investigator:||Peter M Petersen, MD, Ph.D||Rigshospitalet, Denmark|